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Philipp von Rosenstiel7, Lixin Zhang-Auberson7 and Takahiko Saida4,8,9Abstract
Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with
relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated effi-
cacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to
fingolimod.
Methods: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally
randomized to placebo were re-randomized to fingolimod 1.25 mg or 0.5 mg. During the extension, all patients
were switched to open-label fingolimod 0.5 mg.
Results: Magnetic resonance imaging (MRI) and relapse outcomes were maintained or improved in patients
treated with fingolimod for 12 months versus those treated for 6 months. No new safety events were reported over
12 months of treatment. Infections occurred in similar proportions of continuously treated and switched patients,
while cardiac and liver adverse events occurred in fewer continuously treated than switched patients. Four patients
were aquaporin-4 (AQP4) antibody-positive, three of whom showed rapid disease exacerbations within 10 days of
fingolimod initiation.
Conclusion: Continuous fingolimod treatment for up to 12 months was associated with maintained or improved
efficacy and a manageable safety profile, consistent with that previously seen. Results in a small number of patients
suggest lack of benefit in AQP4 antibody-positive patients. Meaningful statistical interpretation was limited by the
small sample size in each treatment group, owing to the number of patients who completed the core study.
Trial registration: ClinicalTrials.gov NCT00670449
Keywords: Aquaporin 4, Fingolimod, Longitudinally extensive spinal cord lesions, Multiple sclerosis, Phase 2 studyBackground
Fingolimod (FTY720) 0.5 mg once daily is the first oral
therapy approved for relapsing multiple sclerosis (MS) in
many countries, including the USA [1], for relapsing-
remitting MS (RRMS) with high disease activity in the
European Union [2], and for the treatment of MS in
Japan [3]. Fingolimod binds to sphingosine 1-phosphate
receptors (S1PRs) on lymphocytes leading to retention
of circulating lymphocytes in the lymph nodes. This* Correspondence: kira@neuro.med.kyushu-u.ac.jp
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reproduction in any medium, provided the orreversible reduction in the number of peripheral blood
lymphocytes is postulated to be mechanistically import-
ant in MS, decreasing the recirculation of autoreactive
lymphocytes and preventing their infiltration into the
central nervous system [4,5].
Global phase 2 and 3 clinical studies have established
a favorable efficacy and safety profile for fingolimod in
predominantly Caucasian populations with MS [6-9]. A
6-month, phase 2, registration study (ClinicalTrials.gov
Identifier NCT00537082) in Japanese individuals dem-
onstrated that fingolimod was associated with reduced
inflammatory brain lesion activity and relapse rate com-
pared with placebo [10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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term efficacy, safety and tolerability of fingolimod in
Japanese patients with relapsing MS. Here we report
12-month efficacy and safety data in individuals con-
tinuously receiving fingolimod and in those whose
treatment was switched to fingolimod during months
7–12 from placebo during months 0–6 (termed the
placebo-fingolimod group). The effects of delaying the
initiation of fingolimod therapy can be assessed by
comparing patients continuously treated with fingoli-




Patients with relapsing MS who had completed 6
months of treatment in the core study were eligible for
the extension study. Eligibility criteria for the core study
have been described in detail elsewhere [10]. In brief, pa-
tients had to be aged 18–60 years and have a diagnosis
of MS according to the revised McDonald criteria [11]
with recent relapses or at least one baseline gadolinium
(Gd)-enhancing T1 lesion on magnetic resonance imaging
(MRI). Patients with longitudinally extensive spinal cord
lesions (LESCLs) of at least three segments (a marker of
neuromyelitis optica [NMO]) at screening were excluded.
Those who completed the core study were invited to give
informed consent to enter the extension phase unless a
study investigator assessed them to be medically ineligible.
Study oversight and design
Information about study oversight has been published
previously [10]. The study (ClinicalTrials.gov Identifier,
NCT00670449) was conducted in accordance with the
International Conference on Harmonisation Guidelines
for Good Clinical Practice [12] and the Declaration of
Helsinki [13] and was overseen by an independent Data
Safety Monitoring Board. Prior to conducting the study,
the Institutional Review Board at each participating
medical centre provided ethical approval of the study
protocol as well as the case report forms, patient infor-
mation and informed consent forms. In the core study,
patients were randomly assigned in a 1:1:1 ratio to re-
ceive once-daily fingolimod capsules, 0.5 mg or 1.25 mg,
or matching placebo for 6 months according to the pro-
cedures previously published [10]. After entering the ex-
tension study, patients either continued to receive their
initial dose of fingolimod (0.5 mg or 1.25 mg) or were
re-randomized 1:1 from placebo to fingolimod 0.5 mg or
1.25 mg under double-blind conditions. Late in the
study, emerging efficacy and safety data from the phase
3 clinical trial program [6,8] indicated a more favorable
benefit-risk profile for fingolimod 0.5 mg than for the
higher fingolimod dose. Based on these results, allpatients who had yet to enter the extension study and
who had received fingolimod 1.25 mg or placebo in the
core study, and patients who were continuing to receive
fingolimod 1.25 mg in the extension study, had their
treatment switched to fingolimod 0.5 mg. The mean
time to switch from administration of the first dose in
the core study was 399 days for the fingolimod 1.25 mg
group and 344 days for the placebo-fingolimod 1.25 mg
group. The majority of patients switched by 12 months
from core study start (fingolimod 1.25 mg, 25/46
[54.3%] patients; placebo-fingolimod 1.25 mg, 12/23
[52.2%] patients).Study endpoints and procedures
Key efficacy variables were MRI inflammatory activity (pro-
portions of patients free of Gd-enhancing T1-weighted or
new/newly enlarged T2-weighted MRI lesions and num-
bers of Gd-enhancing T1-weighted or new/newly enlarged
T2-weighted MRI lesions) and relapse activity (proportions
of patients free of relapses over 12 months, time to the first
confirmed relapse up to 12 months and annualized relapse
rate [ARR]).
Standardized MRI images were obtained as described
previously [7] at screening and months 3, 6, 9 and 12.
Expanded Disability Status Scale (EDSS) scores were
determined at months 6, 9 and 12. Clinical and safety
assessments were conducted on day 1 of entry into the
extension study and at months 6.5, 7, 8, 9, 10, 11 and
12. Vital signs were monitored for at least the first 6
hours after first-dose administration of fingolimod.
Anti-aquaporin-4 (AQP4) antibody test results were
collected retrospectively from medical records of pa-
tients who consented to provide the data during the
study.Statistical methods
The analysis population for MRI endpoints included all
patients who received at least one dose of study drug
during the extension study and had at least one valid
MRI scan during the extension study at month 9 or later
(MRI analysis population). The full analysis set (all pa-
tients who received at least one dose of study drug dur-
ing the extension phase) was used for relapse and EDSS
endpoints (clinical analysis population) and safety end-
points (extension safety population). Efficacy and safety
endpoint data were summarized according to the four
groups (fingolimod 1.25 mg, fingolimod 0.5 mg, placebo-
fingolimod 1.25 mg and placebo-fingolimod 0.5 mg). The
change in dose to fingolimod 0.5 mg during the study for
patients initially randomized to fingolimod 1.25 mg in
either the core study or extension study precluded the
possibility of meaningful formal statistical comparisons.
Therefore, analyses were summarized descriptively.
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Study population
A total of 171 patients were randomized in the core
study across 43 centers in Japan [10]; 147 completed the
trial [10] and 143 agreed to enter the extension phase




57 were allocated to and
received placebo and were
included in the full analysis
set
6 discontinued the study and
study drug
   3 had an adverse event
   1 had a protocol violation
   2 had an unsatisfactory
   therapeutic effect
51 completed the study
   51 were still receiving
   the study drug
Core study
27 were allocated to receive fingol
0.5 mg/day  and were included in 
the full analysis set
23 were allocated to receive fingolimod 
1.25 mg/day and were included in 
 the full analysis set
   3 had an adverse event
5 patients discontinued during
the extension phase
   1 withdrew consent
   1 had a protocol deviation
5 patients had their treatment 
switched to fingolimod 0.5 mg/day 
before month 12 as a result of a
protocol amendment
5 patients discontinued during




Figure 1 Enrollment, randomization and follow-up of study patients.the patients entered into the study had completed the
month 12 visit by August 2010. The 6-month extension
phase was completed by 127 patients. Adverse events
(AEs) accounted for most discontinuations (Figure 1). The
baseline demographics of the extension randomized popu-




57 were allocated to
and received fingolimod
0.5 mg and were included
in the full analysis set
57 were allocated to
fingolimod 1.25 mg
  3 patients discontinued 
  the study before treatment 
  was initiated due to
  protocol deviation
  54 received fingolimod
  1.25 mg and were
  included in the full
  analysis set 
9 discontinued the study
and study drug
   6 had an adverse event
   2 had a protocol violation
   1 withdrew consent
48 completed the study
   48 were still receiving the
   study drug
6 discontinued the study 
and study drug
   6 had an adverse event
48 completed the study
   48 were still receiving the 
   study drug
46 continued to receive
fingolimod 1.25 mg/day at study
entry and were included in the
full analysis set
imod 3 discontinued the study during
the extension phase:
 1 withdrew consent
   1 had abnormal laboratory
   test values
   1 due to administrative
   problems
19 patients had their treatment 
switched to fingolimod 0.5 mg/day 
before month 12 as a result of a
a protocol amendment
47 continued to receive
fingolimod 0.5 mg/day at
study entry and were included
in the full analysis set
3 discontinued the study during
the extension phase
   2 had an adverse event
   1 had an unsatisfactory
   therapeutic effect
Table 1 Baseline demographics and clinical characteristics of patients at entry to core study (extension randomized
population)










Mean (SD) 34.9 (9.0) 35.7 (8.8) 34.2 (9.1) 35.5 (8.4)
Median (range) 34.0 (19–52) 36.0 (18–55) 34.0 (18–52) 34.0 (21–51)
Female, n (%) 33 (70.2) 31 (67.4) 19 (70.4) 14 (60.9)
BMI, kg/m2
Mean (SD) 21.8 (3.2) 22.0 (3.9) 21.0 (2.6) 20.7 (3.1)
Median (range) 21.5 (15.1–32.6) 21.1 (18.1–36.2) 20.8 (15.0–26.2) 20.2 (13.8–28.8)
Disease characteristic
Clinical pattern of MS, n (%)
Relapsing-remitting 44 (93.6) 45 (97.8) 27 (100.0) 23 (100.0)
Secondary progressive 3 (6.4) 1 (2.2) 0 (0.0) 0 (0.0)
Duration of MS since first symptom, years
Mean (SD) 8.2 (6.6) 7.6 (5.5) 8.4 (8.1) 8.4 (7.2)
Median (range) 6.4 (1–26) 6.2 (0–21) 5.4 (1–27) 5.9 (1–24)
Number of relapses within previous year
Mean (SD) 1.4 (0.9) 1.5 (1.0) 2.1 (2.1) 1.4 (0.7)
Median (range) 1.0 (0–3) 1.0 (0–4) 2.0 (1–12) 1.0 (0–3)
Number of relapses within previous 2 years
Mean (SD) 2.1 (1.3) 2.2 (1.6) 3.2 (4.0) 2.5 (1.4)
Median (range) 2.0 (0–7) 2.0 (0–6) 2.0 (1–22) 2.0 (0–5)
EDSS score
Mean (SD) 2.4 (1.9) 1.9 (1.7) 1.9 (1.6) 2.4 (1.6)
Median (range) 2.0 (0.0–6.0) 2.0 (0.0–6.0) 1.5 (0.0–5.0) 2.0 (0.0–5.5)
MRI characteristics
Patients free of Gd-enhancing lesions
n (%) 28 (59.6) 22 (47.8) 13 (48.1) 17 (73.9)
Number of Gd-enhancing lesions
Mean (SD) 1.0 (1.59) 1.7 (2.42) 1.7 (2.45) 0.7 (1.49)
Median (range) 0.0 (0–5) 1.0 (0–9) 1.0 (0–9) 0.0 (0–5)
Number of T2 lesions
Mean 30.3 (22.83) 34.6 (24.15) 28.9 (23.22) 33.3 (23.11)
Median (range) 24.0 (4–100) 29.5 (5–119) 23.0 (3–98) 35.0 (1–91)
MS medication history
Treatment-naïve patients, n (%) 16 (34.0) 21 (45.7) 16 (59.3) 8 (34.8)
Previously treated patients, n (%) 31 (66.0) 25 (54.3) 11 (40.7) 15 (65.2)
Any interferon beta 30 (63.8) 25 (54.3) 10 (37.0) 14 (60.9)
Other MS medications 9 (19.1) 6 (13.0) 2 (7.4) 3 (13.0)
Abbreviations: BMI body mass index; EDSS Expanded Disability Status Scale; Gd gadolinium; MRI magnetic resonance imaging; MS multiple sclerosis;
SD standard deviation.
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randomized population appeared to be generally similar
across treatment groups (Table 1) with the exception ofmean number of relapses in the previous 1 or 2 years
and the proportion of patients free of Gd-enhancing
lesions.
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MRI outcomes
In patients switched from placebo to fingolimod therapy,
inflammatory MRI activity appeared to be reduced in
the extension study compared with the core phase, with
apparently consistent effects across the two fingolimod
doses (Table 2). The proportions of patients free of Gd-
enhancing lesions at months 9 and 12 were markedly
higher than those at months 3 and 6, as were the pro-
portions of patients free of new/newly enlarged T2
lesions over months 7–12 versus months 0–6. Mean
numbers of Gd-enhancing and new/newly enlarged T2
lesions were reduced in switched patients in the exten-
sion study compared with the core phase. In patients
continuously treated with fingolimod, the proportions of







MRI outcomes (MRI analysis population) n = 45
Patients free of Gd-enhancing lesions, n/totala (%)
Both months 3 and 6 35/45 (77.8) 37
Both months 9 and 12 38/45 (84.4) 36
Number of Gd-enhancing lesions
Month 6 0.1 (0.32) 0
Month 12 0.0 (0.15) 0
Patients free of new/newly enlarged T2 lesions, n/totala (%)
Months 0–6 30/45 (66.7) 24
Months 7–12 39/45 (86.7) 37
Number of new/newly enlarged T2 lesions
Months 0–6 0.9 (2.1) 1
Months 7–12 0.3 (1.1) 0
Clinical outcomes (clinical analysis
population)
n = 47
Patients free of relapse, nb (%)
Months 0–6 38 (80.9) 3




EDSS score change from core baseline
Month 6 0.00 (0.36) −0
Month 12 −0.02 (0.46) −0
All values are means (standard deviations) unless otherwise indicated.
aThe numerators (n) indicate the number of patients free of Gd-enhancing lesions o
of patients for whom MRI data were available. The percentages were calculated as
bAbsolute number of patients free of confirmed relapses.
cCalculated as total number of confirmed relapses per treatment arm/total number
Abbreviations: EDSS Expanded Disability Status Scale; Gd gadolinium; MRI magneticenlarged T2 lesions remained high or increased slightly
in the extension study compared with the core phase.
Mean numbers of Gd-enhancing lesions decreased to
zero at month 12, and the number of new/newly en-
larged T2 lesions decreased over months 7–12 versus
months 0–6. Over 12 months of treatment, the propor-
tions of patients who were free of new/newly enlarged
T2 lesions were higher and the mean numbers of new/
newly enlarged T2 lesions were lower in the groups that
received continuous fingolimod for 12 months compared
with the groups that switched from placebo to fingoli-
mod at month 6 (Figure 2, A and C).
Clinical outcomes
In individuals switched from placebo to fingolimod ther-
apy, the proportions of patients who were free of relapsend extension phases (months 7–12) (MRI and clinical







n = 42 n = 23 n = 20
/42 (88.1) 6/23 (26.1) 11/20 (55.0)
/42 (85.7) 16/23 (69.6) 13/19 (68.4)
.2 (1.08) 1.3 (1.84) 1.2 (1.96)
.0 (0.15) 0.1 (0.31) 0.2 (0.54)
/42 (57.1) 5/23 (21.7) 10/19 (52.6)
/42 (88.1) 13/21 (61.9) 11/17 (64.7)
.0 (2.0) 7.7 (14.5) 5.1 (6.8)
.2 (0.5) 0.6 (1.2) 0.5 (0.9)
n = 46 n = 27 n = 23
8 (82.6) 18 (66.7) 14 (60.9)
1 (89.1) 24 (88.9) 21 (91.3)
0.39 0.97 1.22
0.28 0.26 0.21
.21 (0.59) 0.04 (1.00) 0.26 (0.78)
.02 (0.83) −0.32 (0.66) −0.11 (0.95)
r new/newly enlarged T2 lesions; the denominators (total) indicate the number
n/total × 100.







































































































































































































































Figure 2 Clinical and magnetic resonance imaging (MRI) endpoints over months 0–12. Between-groups comparisons for (A) proportions of
patients who were free of new/newly enlarged T2 lesions, (B) proportions of patients who were relapse-free (absolute number of patients free of
confirmed relapses), (C) the cumulative number of new/newly enlarged T2 lesions and (D) the annualized relapse rate (calculated as total number
of confirmed relapses per treatment arm divided by total number of days on the study for all patients per treatment arm, multiplied by 365.25).
The MRI analysis population was used for the proportion of patients free of new/newly enlarged T2 lesions (A) and cumulative number of new/newly
enlarged T2 lesions (C). The extension full analysis set was used for the proportion of patients relapse-free (B) and annualized relapse rate (D).
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and ARRs over months 7–12 were markedly reduced
compared with months 0–6 (Table 2). Kaplan-Meier plots
demonstrated a decreased risk of relapse over months 7–
12 compared with months 0–6 for those switching treat-
ment from placebo to fingolimod (Figure 3). In patients
continuously treated with fingolimod, the proportion of
patients who were free of relapse remained high in the ex-
tension study compared with the core phase, while ARRs
further decreased in the extension study compared with
the core phase. The risk of relapse on Kaplan-Meier plots
remained similar in the continuous fingolimod 1.25 mg
and 0.5 mg groups over the core and extension phases
(Figure 3). The proportions of patients who were freeof relapse were higher, and ARRs were lower, for indi-
viduals who received continuous fingolimod therapy for
12 months compared with patients whose treatment
was switched from placebo to fingolimod at month 6
(Figure 2, B and D).
Safety and tolerability
A higher proportion of patients experienced an AE in
the 1.25 mg groups relative to the 0.5 mg groups during
the extension phase (months 7–12) in both continuous
fingolimod and switched treatment groups (Table 3).
The incidence of serious AEs was lower in the continu-
ously treated groups than in the switched groups, and











0 30 60 90 120 150
Time to first relapse (days)


































Figure 3 Kaplan-Meier plot of time to first confirmed relapse up to month 12 (extension full analysis set).
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http://www.biomedcentral.com/1471-2377/14/210.5 mg group during the extension phase (Table 3). The
total incidence of AEs leading to study drug discontinu-
ation was lower in the continuously treated groups than
the switched groups (Table 3). No AE leading to study
drug discontinuation occurred in more than one patient
in each treatment group.
Infections and infestations were the most commonly
reported AEs and appeared to occur in generally similar
proportions of continuously treated and switched pa-
tients, but were slightly more common in the fingolimod
1.25 mg groups than the 0.5 mg groups (Table 3). No in-
fections were reported as serious AEs (Table 3) and no
infections were responsible for study drug discontinu-
ation. Nasopharyngitis was the most commonly reported
AE, occurring in 25.9–41.3% of patients. Influenza was
more frequent in the placebo-fingolimod 1.25 mg switch
group than in the continuous fingolimod 1.25 mg group
and did not occur in the fingolimod 0.5 mg treatment
groups. Herpes zoster infections occurred in 3.7% and
4.3% of switched patients (placebo-fingolimod 0.5 mg
and placebo-fingolimod 1.25 mg, respectively), but were
absent in both continuously treated groups.
The only recorded cardiac AEs were second-degree
atrioventricular (AV) block and bradycardia, which each
occurred in 3 (13%) patients in the placebo-fingolimod
1.25 mg group, and all occurred at first dose (Table 3).
Of these, two of the bradycardia cases were reported as
serious AEs.
Abnormal liver function tests and liver enzyme eleva-
tions occurred more frequently, and led to study drug
discontinuation more frequently, in the switched pa-
tients during the extension study phase than in the con-
tinuously treated patients (Table 3). In switched patients
with abnormal liver function test results, alanine amino-
transferase (ALT), aspartate aminotransferase (AST) andγ-glutamyl transferase (GGT) levels were elevated from
month 6.5 onwards and reached a maximum between
months 9 and 12. In continuously treated patients with
abnormal test results, elevations in ALT, AST and GGT
were observed from 15 days after initiation of treatment
in the core study: a maximum level was reached at
month 3 for ALT and AST and at month 6.5 for GGT;
levels of ALT, AST and GGT then remained stable up to
month 12.
No deaths, malignancies or confirmed cases of macular
edema were reported in patients treated continuously with
fingolimod or in switched patients over months 0–12.
However, a 42-year-old man in the fingolimod 0.5 mg
group died approximately 1 year after discontinuing
study drug (discontinuation was due to a serious MS
relapse). The cause of death was diagnosed at autopsy
as Epstein-Barr virus (EBV)-related B-cell lymphoma of
the brain accompanying non-methotrexate-associated
iatrogenic immunodeficiency-associated lymphoprolif-
erative disorder of the lung, kidney, thyroid and je-
junum (further details are provided in the Additional
file 1). Although the B-cell lymphoma was diagnosed 5
months after discontinuation of study drug and after a
relatively brief period of treatment with fingolimod of 9
months, a relationship between the B-cell lymphoma
and the study medication cannot be excluded and was
suspected by the investigator.
Clinical courses and safety events in patients positive for
anti-AQP4 antibodies
Anti-AQP4 antibody test results were obtained from one
patient during the processing of a serious AE (multifocal
white matter lesions in an individual in the placebo-
fingolimod 1.25 mg group) and retrospectively from the
medical histories of a further 67 patients. Of these 68
Table 3 Most frequent adverse events and serious adverse events during the extension phase
(extension safety population)
Adverse event, n (%) Placebo-fingolimod
0.5 mg (n = 27)
Placebo-fingolimod
1.25 mga (n = 23)
Continuous fingolimod
0.5 mg (n = 47)
Continuous fingolimod
1.25 mga (n = 46)
Any adverse event 22 (81.5) 23 (100) 35 (74.5) 41 (89.1)
Any serious adverse event 1 (3.7) 4 (17.4) 1 (2.1) 0 (0.0)
Any adverse event leading to discontinuation of
study drug
5 (18.5) 3 (13.0) 2 (4.3) 0 (0.0)
Any infection or infestation adverse event 11 (40.7) 14 (60.9) 23 (48.9) 28 (60.9)
Most commonly reported adverse eventsb
Nasopharyngitis 7 (25.9) 7 (30.4) 16 (34.0) 19 (41.3)
Liver function test abnormal 4 (14.8) 9 (39.1) 3 (6.4) 4 (8.7)
Leukopenia 4 (14.8) 1 (4.3) 0 (0.0) 3 (6.5)
Bradycardia 0 (0.0) 3 (13.0) 0 (0.0) 0 (0.0)
Influenza 0 (0.0) 3 (13.0) 0 (0.0) 2 (4.3)
Second-degree atrioventricular block 0 (0.0) 3 (13.0) 0 (0.0) 0 (0.0)
Headache 0 (0.0) 2 (8.7) 5 (10.6) 0 (0.0)
Lymphocyte count decreased 1 (3.7) 2 (8.7) 1 (2.1) 2 (4.3)
Lymphopenia 0 (0.0) 2 (8.7) 0 (0.0) 3 (6.5)
γ-glutamyltransferase increased 1 (3.7) 2 (8.7) 1 (2.1) 0 (0.0)
White blood cell count decreased 0 (0.0) 2 (8.7) 0 (0.0) 1 (2.2)
Eczema 0 (0.0) 1 (4.3) 1 (2.1) 4 (8.7)
Rash 2 (7.4) 1 (4.3) 1 (2.1) 0 (0.0)
Alanine aminotransferase increased 2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0)
Blood triglycerides increased 2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0)
Dental caries 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.5)
Diarrhea 1 (3.7) 0 (0.0) 2 (4.3) 3 (6.5)
Stomatitis 1 (3.7) 1 (4.3) 0 (0.0) 3 (6.5)
Pharyngitis 0 (0.0) 1 (4.3) 1 (2.1) 3 (6.5)
Tinea pedis 1 (3.7) 1 (4.3) 3 (6.4) 0 (0.0)
Skin papilloma 0 (0.0) 0 (0.0) 3 (6.4) 0 (0.0)
Serious adverse events
Bradycardia 0 (0.0) 2 (8.7) 0 (0.0) 0 (0.0)
Leukoencephalopathyc 0 (0.0) 1 (4.3) 0 (0.0) 0 (0.0)
Multiple sclerosis relapse 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0)
Neuromyelitis optica 1 (3.7) 0 (0.0) 0 (0.0) 0 (0.0)
Abortion induced 0 (0.0) 1 (4.3) 0 (0.0) 0 (0.0)
aAll patients receiving fingolimod 1.25 mg/day were switched to fingolimod 0.5 mg/day after the fingolimod 1.25 mg/day dose was discontinued from all multiple
sclerosis clinical studies.
bAdverse events reported in 5% of patients or more in any treatment group during the extension phase.
cThis single case of leukoencephalopathy was not of the type associated with progressive multifocal leukoencephalopathy.
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entered the extension phase. The clinical courses and
safety events in these patients are described in Table 4
and Additional file 1. In two of these patients, leukoen-
cephalopathy (multifocal white matter lesions; patient 4
in Table 4) and NMO (patient 3 in Table 4) were re-
ported during months 7–12 as serious AEs (Table 3).Discussion
This extension study provides additional data with which
to establish the efficacy and safety profile of fingolimod
in Japanese patients with relapsing MS. Overall, the effi-
cacy and safety findings were consistent with those in the
core study [10]. Patients who received continuous fingoli-
mod treatment for 12 months experienced sustained or
Table 4 Summary of clinical course and safety events in patients positive for anti-AQP4 antibodies
Patient Treatment Clinical course and safety events (onseta)
Continuous fingolimod
1 Fingolimod 0.5 mg Bradycardia (day 2); chest discomfort (day 2); enlargement of a pre-existing spinal cord lesion, LESCL,
pons and midbrain lesions (day 9); myelitis and LESCL (day 145); diplopia, right upper limb paresis,
multiple lesions in the cervical and thoracic cord, brainstem, cerebellum and cerebrum (day 235)
2b Fingolimod 1.25 mg Decreased heart rate (day 1); myelitis relapse (day 5); decreased heart rate (day 5; day 1 after drug
interruption); abnormal liver function test result (day 85); asymptomatic multiple enhancing lesions
in the bilateral cerebral white matter and an asymptomatic enhancing spinal cord lesion at C6
(6 days after fingolimod discontinuation); conduction and amnestic aphasia (3 weeks after fingolimod
discontinuation)
Switched from placebo to fingolimod
3 Placebo/fingolimod 0.5 mg Recurrence of right optic neuritis and myelitis (day 29 of extension phase); dysarthria, right ataxia
and weakness, right frontal lobe lesion (3 months); right upper limb weakness (4 months); left parietal
lobe lesion, left paresthesia, dizziness and eye movement disturbance (1 month after fingolimod
discontinuation)
4 Placebo/fingolimod 1.25 mg Relapse showing left hemispheric symptoms and exacerbation of cerebral and cerebellar white matter
lesions (day 9 in the extension phase)c
aDays after initiation of fingolimod in core study or extension phase.
bThis patient discontinued from the study on day 78 during the core phase.
cThis case was not diagnosed as progressive multifocal leukoencephalopathy.
Abbreviations: AQP4 aquaporin 4; LESCL longitudinally extensive spinal cord lesion.
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and had reduced relapse rates and MRI lesion activity
compared with those in the core study. Furthermore, effi-
cacy endpoints were consistently superior at month 12 in
the continuous fingolimod groups compared with the
placebo-fingolimod groups.
The results of this trial are consistent with those of
previously reported clinical studies of fingolimod in pre-
dominantly Caucasian populations [6-8,14]. The results
are clinically important because there are genetic, meta-
bolic and lifestyle differences between Caucasian and
Japanese populations [15,16], as well as differences in
the presentation of MS that may affect response to ther-
apy. It has been postulated that the higher prevalence of
optic-spinal MS (OSMS) in Japan versus Western coun-
tries is due to a higher prevalence of NMO, which is also
a demyelinating disease with some overlapping symp-
toms to MS and is characterized by LESCLs [10]. Historic-
ally, no distinction was made between MS and NMO.
However, debate continues about whether OSMS is actu-
ally a distinct disease from both MS and NMO because
many Japanese patients who present with OSMS are sero-
negative for anti-AQP4 (a marker for NMO) and remain
free from LESCLs [17]. This study was designed to ex-
clude NMO patients by using the presence of LESCLs on
spinal MRI as exclusion criteria at screening. Patients were
eligible for the study if the diagnosis of MS was confirmed
by the study investigators and if they fulfilled MRI criteria.
There was no exclusion criterion related to the presence
of anti-AQP4 antibodies. The anti-AQP4 antibody test re-
sults were collected from medical records retrospectively
for patients who consented to provide the data upon oc-
currence of a severe adverse event.In both the continuous fingolimod and placebo-
fingolimod groups, the safety profile was consistent with
that seen in previous clinical studies [6,8,14,18]. No new
AEs, deaths, or fatal or serious infections were reported
during the extension phase. The cardiac AEs reported in
the placebo-fingolimod groups (transient asymptomatic
bradycardia and second-degree AV block) were consist-
ent with those observed in the core study and in global
clinical studies [6-8,14], and have been shown to be an
expected consequence of the interaction of fingolimod
with S1PRs on atrial myocytes [5,19]. Liver enzyme ele-
vations were more common in the switch groups than in
the continuous fingolimod groups, consistent with the
early onset and transient nature of transaminase eleva-
tions with fingolimod [6,8,14]. Global fingolimod studies
have identified macular edema [6-8] as an AE of low fre-
quency but of particular interest. In this relatively small
study, specific safety monitoring did not identify any
cases of macular edema up to month 12. Three cases of
lymphoma, including the case of EBV-positive B-cell
lymphoma described above, have been reported in the
overall fingolimod clinical development program [20].
This is in line with epidemiological data reporting the
background incidence of lymphoma (19.1 cases per
100,000 person-years [21]). However, because of the low
incidence of malignancies and the limited duration of ex-
posure, firm conclusions on an increased risk of malignan-
cies with fingolimod treatment cannot be drawn yet.
Although it was reported that positivity for antibodies
to AQP4 and evidence of LESCLs distinguish NMO
from MS with 76% and 98% sensitivity, respectively [22],
4/68 (5.9%) patients in this extension study, which
excluded individuals with LESCLs, were anti-AQP4
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cases of NMO were excluded. Exacerbation of NMO has
been reported in Japanese patients treated with inter-
feron beta for MS who were subsequently found to be
positive for antibodies to AQP4 [23]. In addition, a case
study of a patient who developed extensive brain lesions
14 days after initiation of fingolimod 0.5 mg in the phase
3 TRANSFORMS (Trial Assessing Injectable Interferon
versus FTY720 Oral in Relapsing-Remitting Multiple
Sclerosis) has been published [24]. After this patient
tested positive for anti-AQP4 antibodies, the initial diag-
nosis of MS was changed to NMO.
In the present study, three individuals positive for anti-
bodies to AQP4 (patients 1, 2 and 4 from Table 4) devel-
oped relapses very rapidly after introduction of either
dose of fingolimod (2, 5 and 9 days after, respectively).
This is in accordance with the time-course of exacerba-
tion in the previous case report of NMO during fingoli-
mod therapy [24]. In the core study, the proportion of
relapses that occurred in the 2 weeks after study entry
out of the total number of relapses was relatively low
(30%, 17% and 27% for the fingolimod 1.25 mg, 0.5 mg
and placebo groups, respectively). Thus, although causal-
ity cannot be established from this retrospective analysis,
it may be speculated that the relapses within the first 2
weeks following fingolimod initiation in patients positive
for antibodies to AQP4 represented exacerbation of dis-
ease due to the temporal sequence of events here and in
the previous case report of NMO [24]. A fourth anti-
AQP4-positive patient (patient 3 from Table 4) pre-
sented with three relapses during 129 days of fingolimod
therapy; however, this individual was considered to have
high disease activity as indicated by additional relapses
before and after fingolimod therapy. The frequent re-
lapses during fingolimod therapy in patient 3 may also
be partly attributable to exacerbation of relapse. In all
anti-AQP4-positive patients, the nature of relapses de-
veloped after commencing fingolimod appeared to be
similar to previous relapses (myelitis in patients 1, 2 and
3, and multifocal cerebral and cerebellar white matter le-
sions in patient 4). Accordingly, it is conceivable that
fingolimod did not alter the nature of the disease; rather,
it might have enhanced the original disease activity
through an unknown mechanism. In the present study,
corticosteroid pulse therapy appeared to alleviate the ex-
acerbations that emerged after fingolimod initiation,
leaving little or no residual effects (except in patient 4,
who had moderate residual disability despite intravenous
immunoglobulin administration in addition to steroid
pulse therapy), although these observations on cortico-
steroid effects did not have a control for comparison.
Together, the present findings suggest that caution is
needed if introducing fingolimod in patients with idio-
pathic central nervous system demyelinating diseasewith atypical MS features without testing for anti-AQP4
antibodies first.
The limitations of this observational extension study
include the need to switch treatment for all patients re-
ceiving fingolimod 1.25 mg to 0.5 mg and the small
sample size, which prevented meaningful statistical in-
terpretation – while larger cohorts would be desirable,
the low incidence of MS in Japan presents a significant
recruitment challenge.
Conclusion
Continuous fingolimod treatment for MS over 12 months
is associated with consistent efficacy outcomes with no de-
terioration in the predictable and manageable safety profile.
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